We are a bioscience company with product development in the following areas:
Phyto products
- Inflammation
- Diabetes
- Degenerative Brain Diseases
- Strokes
- Kidney
- Stroke
Because of the group’s interest in blood sugar and neurodegenerative therapeutics, research and development activities for the company have been directed and focused on the production of new therapeutics. All the company’s efficacy studies for the therapeutic activities have been and will continue to be outsourced to some of our regional partners, in collaboration with other international universities and organizations. The company’s personnel include professionals with advanced degrees and long term professional experience. The group’s scientists have been working diligently for the past forty (40) years and are prepared to do all they can to move the company’s technologies forward to product development and commercialization. Regarding the Phyto-products or the plant derived medicines and therapeutics, the company’s researchers work in collaboration with several international researchers in various countries as well as indigenous herbal medicine practitioners, with extremely valuable knowledge passed down from generations before the dawn of records and documentation.
DIABETES
The diabetic epidemic is a danger to the human race on a global scale. For the past forty (40) years, the most important Phyto-product activity of the company has been the intent of controlling pancreatic functions, insulin production, management of blood sugar levels, inflammation control or its elimination. During this period, the group has identified useful and important plant species across several countries and regions of the world. These plants have the capabilities of controlling blood sugar levels and prevent insulin resistance. The group’s scientists have been collaborating with indigenous people and practitioners of traditional plant medicine worldwide to gain more knowledge in the identification and extraction of important plant chemicals. The diabetic research and development program have been centered in West Africa and Japan. It is estimated by The World Health Organization (WHO), that eight out of every one thousand people suffer from various stages of diabetes. Notably, it is becoming increasingly common among non-elderly and children as well. This increase in the incidence of diabetes can be directly correlated to lifestyle issues, parasitic infections, healthcare, and economic problems whose impact is reflected in its treatment and complications that cause poor quality of life. Type 2 diabetes is currently deemed as one of the silent and destructive factors regarding the functioning of the β cells of the pancreas and insulin resistance in various target tissues. Healthy β cells compensate for insulin resistance with an increase in insulin secretion, but failure in this compensatory mechanism leads to glucose intolerance. Once hyperglycemia occurs, β-cell function deteriorates, and insulin resistance worsens.
According to the world health organization, the highest numbers of diabetes patients are in the following countries: India, China, USA, Caribbean followed closely by Middle Eastern countries and currently certain countries in Africa. Diabetes can be classified into three major categories with additional sub-categories (Samar A, Antor et, al. (Biomedicine & Pharmacotherapy, vol 168, dec 2023,115734):
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Gestational diabetes Mellitus
Besides the three identified above, there are other minor common types of diabetes mellitus, which are equally dangerous to the human health.:
According to the International Diabetes Foundation in 2021, approximately 537 million people were affected with diabetes, at a cost of US$966 Billion. In 2024, the estimated cost was US$1.014 Billion. They also projected that in 2045 there will be 783 million people with diabetes, with an economic cost which will surpass US$1045 Billion. The World Health Organization (WHO) also confirmed that, half the world’s population with diabetes, do not even know they have it (Jamal Hossain et all Health Sci Rep. 2024 (Mar.22;7 (3); e2024. However, the most common type of diabetes is Type 2 diabetes. Notably, it is becoming increasingly common, in non-elderly and children as well.
Notably, diabetes is becoming increasingly common among non-elderly and children as well. This increase in the incidence of diabetes could be attributed to lifestyle issues, healthcare and economic problems whose impact is reflected in its treatment and complications that is caused by poor quality of life. Type 2 diabetes is currently deemed one of the pandemics of the 21st century which is ordinarily associated with a combination of failure in the functioning of the β cells of the pancreas and insulin resistance in various target tissues (Marlon Cerf Frontiers in Endocrinology 2013 Mar 27,4;37). Healthy β cells compensate for insulin resistance with an increase in insulin secretion, but failure in this compensatory mechanism leads to glucose intolerance. Once hyperglycemia occurs, β-cell function deteriorates, and insulin resistance worsens.
Our group of researchers have identified certain plants containing secondary metabolites with inherent hypoglycemic properties, aiding in regulating blood glucose levels. We further noted several of these species and their secondary metabolites have shown effectiveness in improving insulin sensitivity, and mitigating the adverse effects associated with diabetes. Thus, the complex array of bioactive compounds within medicinal plants, which offers a multifaceted approach to diabetes management. For example, the flavonoids, alkaloids, polyphenols, and terpenoids found in these medicinal plants provide antioxidant, anti-inflammatory, and anti-glycation effects, mitigating oxidative stress and inflammation often associated with diabetic complications. These special properties have enabled our group to obtain patents for our diabetic therapeutic in Japan and waiting for the worldwide patents to be issued. We are also preparing to submit patents for specific and specialized extracts and the cellular mechanisms of isolated secondary metabolites in preclinical and clinical studies.
Regarding our ongoing research and development efforts, it could be said that other plant species have also been identified to be effective in improving the efficiency of the liver and the pancreatic functions. Currently known and approved drugs for the treatment of diabetes employ antidiabetic mechanisms and action that include the inhibition of alpha-glucosidase and alpha-amylase in the digestive tract. This therefore decreases the uptake of glucose through its transporters by stimulating the release of insulin. Various reviews of the current pharmaceutical drugs for all types of diabetes have been documented as not being completely effective and but creates dependency, without the desired results. Thus the necessity for improved approaches in diabetes treatment and management. Furthermore, from our research and development activities as noted above, we have identified additional number of plant species and their extracts;
which have shown tremendous promise in the elimination and reversal of Type-2 diabetes, for which we been granted patents for their phytochemical extracts and their mode of action. At present, the most common drug on the market for glucose control are, Sulfonylureas, Glinides, Thiazolidinediones, Alpha-glucoside inhibitors and Metformin. It is important to note that Metformin was originally derived from French lilac (Galega officinalis), a guanidine-rich plant used in European folk medicine. Interestingly, several laboratories worldwide are also racing to find similar drugs, by studying various plants.
Aobanna (Commelina cummunis) var. hortensis;( Makio Shibano et al.) one of our discoveries, further confirmed that the phytochemicals in this plant have also have strong inhibitory activity on alpha-glucosidase.
When the extracts and powders were tested, they reduced blood sugar levels significantly Their extract and powder are important food materials for prophylaxis against type-2 diabetes. Also, eleven other important glucosidases complexes, have been found and labeled according to us from independent laboratories analysis.
This patented product is ready for premarket testing and labeling decisions for international markets. Aobanna extract can be used as tea, mixed in with soup used for baking and in general cooking. The simplicity of the multipurpose usage is to make it possible for people with Type-2 diabetes to be able to use this extract anytime without necessarily feeling that they are taking a regimented supplement which has no side effect.
We are currently in the market seeking funding to commercialize our newly formulated diabetic therapeutics.